ACET Straddle Strategy
ACET (Adicet Bio, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
ACET (Adicet Bio, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $78.2M, a beta of 1.59 versus the broader market, a 52-week range of 6.01-17.44, average daily share volume of 114K, a public-listing history dating back to 2018, approximately 152 full-time employees. These structural characteristics shape how ACET stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.59 indicates ACET has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a straddle on ACET?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current ACET snapshot
As of June 30, 2026, spot at $8.73, ATM IV 289.40%, IV rank 56.71%, expected move 82.97%. The straddle on ACET below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this straddle structure on ACET specifically: ACET IV at 289.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 82.97% (roughly $7.24 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ACET expiries trade a higher absolute premium for lower per-day decay. Position sizing on ACET should anchor to the underlying notional of $8.73 per share and to the trader's directional view on ACET stock.
ACET straddle setup
The ACET straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ACET near $8.73, the first option leg uses a $8.73 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ACET chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ACET shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $8.73 | N/A |
| Buy 1 | Put | $8.73 | N/A |
ACET straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
ACET straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on ACET. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on ACET
Straddles on ACET are pure-volatility plays that profit from large moves in either direction; traders typically buy ACET straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
ACET thesis for this straddle
The market-implied 1-standard-deviation range for ACET extends from approximately $1.49 on the downside to $15.97 on the upside. A ACET long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ACET IV rank near 56.71% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on ACET should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ACET options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ACET-specific events.
ACET straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ACET positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ACET alongside the broader basket even when ACET-specific fundamentals are unchanged. Always rebuild the position from current ACET chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on ACET?
- A straddle on ACET is the straddle strategy applied to ACET (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ACET stock trading near $8.73, the strikes shown on this page are snapped to the nearest listed ACET chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ACET straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ACET straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 289.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ACET straddle?
- The breakeven for the ACET straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ACET market-implied 1-standard-deviation expected move is approximately 82.97%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on ACET?
- Straddles on ACET are pure-volatility plays that profit from large moves in either direction; traders typically buy ACET straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current ACET implied volatility affect this straddle?
- ACET ATM IV is at 289.40% with IV rank near 56.71%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.